[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335010-105":59,"doc-detail-335010-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","modeling-human-gastric-cancers-in-immunocompetent-mice-review","Modeling human gastric cancers in immunocompetent mice - Review","","Gastric cancer (GC) causes major cancer-related mortality worldwide and is driven by multiple genetic and environmental influences, presenting marked anatomic variation and strong cellular, histological, and molecular heterogeneity. This heterogeneity has limited complete understanding of GC pathology and the development of effective therapies. Over the past decade, advances in molecular subtyping and immune microenvironment profiling clarified evolutionary routes and tumor dynamics. Preclinical immunocompetent mouse models, especially those with organoid culture and clinical integration, support mechanistic studies of immune evasion and enable novel therapeutic strategy development.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/modeling-human-gastric-cancers-in-immunocompetent-mice-review/335010/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/modeling-human-gastric-cancers-in-immunocompetent-mice-review/335010.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are current gastric cancer treatments often limited in advanced disease?","Question",{"text":112,"@type":113},"Surgery and radio-chemotherapy face frequent challenges in advanced or metastatic stages, partly due to the lack of early diagnosis markers. Many patients also do not respond well to immunotherapies and targeted therapies, reflecting the disease’s heterogeneity.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What has enabled deeper understanding of gastric cancer in recent years?",{"text":117,"@type":113},"Progress includes molecular subtyping, characterization of the immune microenvironment, and defining evolutionary paths and dynamics. Tools such as genomic approaches and single-cell RNA sequencing have helped resolve cellular and transcriptional diversity in primary and metastatic lesions.",{"name":119,"@type":110,"acceptedAnswer":120},"How do immunocompetent mouse models contribute to studying gastric cancer?",{"text":121,"@type":113},"Immunocompetent mouse models that mimic key cellular and molecular features of human GC provide platforms to elucidate mechanisms of GC pathology and immune evasion. Combined with organoid culture and clinical studies, these models also support the development of new therapeutic strategies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335010,1790591384,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Cancer Biol Med 2024. doi: 10.20892/j.issn.2095-3941.2024.0124  \nREVIEW  \nModeling human gastric cancers in immunocompetent mice  \nWeihong Zhang1,2, Shilong Wang2, Hui Zhang2, Yan Meng1, Shi Jiao2, Liwei An1, Zhaocai Zhou2,3  \n1 Department of Stomatology, Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Tongji University Cancer Center, Tongji University School of Medicine, Shanghai 200072, China; 2State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai 200032, China; 3Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing 211166, China  \n\n| ABSTRACT | Gastric cancer (GC) is a major cause of cancer-related mortality worldwide. GC is determined by multiple (epi)genetic and |\n| --- | --- |\n| KEYWORDS | environmental factors; can occur at distinct anatomic positions ofthe stomach; and displays high heterogeneity, with different cellular origins and diverse histological and molecular features. This heterogeneity has hindered efforts to fully understand the pathology of GC and develop efficient therapeutics. In the past decade, great progress has been made in the study of GC, particularly in molecular subtyping, investigation of the immune microenvironment, and defining the evolutionary path and dynamics. Preclinical mouse models, particularly immunocompetent models that mimic the cellular and molecular features of human GC, in combination with organoid culture and clinical studies, have provided powerful tools for elucidating the molecular and cellular mechanisms underlying GC pathology and immune evasion, and the development of novel therapeutic strategies. Herein, we first briefly introduce current progress and challenges in GC study and subsequently summarize immunocompetent GC mouse models, emphasizing the potential application of genetically engineered mouse models in antitumor immunity and immunotherapy studies.\u003Cbr>Gastric cancer; heterogeneity; mouse model; GEMM; immunocompetent |\n\nIntroduction  \nGastric cancer (GC) is a major cause of cancer-related mortality worldwide1,2 . To date, surgery and radio-chemotherapy remain the major clinical treatments for GC. However, these treatments are frequently challenged by patients presenting in advanced or metastatic disease stages, because of a lack of early diagnosis markers3. Recently, immunotherapies such as anti-PD1/PD-L14,5 and targeted therapy (anti-Her2/ Claudin18 .2)6,7 have entered clinical trials and have been used as tumor treatments. However, many or even most patients with GC do not respond well to these treatments, thus emphasizing the highly heterogeneous nature of GC and  \nCorrespondence to: Liwei An and Zhaocai Zhou  \nE-mail: [lwan@tongji.edu.cn](lwan@tongji.edu.cn) and [zhouzhaocai@fudan.edu.cn](zhouzhaocai@fudan.edu.cn)  \nORCID ID: [https://orcid.org/0000-0003-4514-5476](https://orcid.org/0000-0003-4514-5476) and  \n[https://orcid.org/0000-0002-5441-3922](https://orcid.org/0000-0002-5441-3922)  \nReceived April 4, 2024; accepted May 14, 2024;  \npublished online June 28, 2024. Available [at www.cancerbiomed.org](at www.cancerbiomed.org)  \n©2024 The Authors. Creative Commons Attribution-NonCommercial 4.0 International License  \nthe urgent need for in-depth understanding of GC pathology. Heterogeneity remains a major barrier to GC management8.  \nThe first aspect of GC heterogeneity is the ever-refined subtyping. Traditional Lauren classification of GC includes intestinal-type, diffuse-type, and mixed-type GC9. Recent studies have comprehensively characterized the molecular features of gastric adenocarcinoma. In a milestone in this regard, The Cancer Genome Atlas project, at the molecular level, has revealed 295 primary GCs and defined 4 GC subtypes including Epstein-Barr virus-positive, microsatellite instability, chromosomal instability and genomic stability10. Single cell RNA sequencing (scRNA-seq) has been applied to ","cbCaiugVmEQrjwvg","https://ap.wps.com/l/cbCaiugVmEQrjwvg","pdf",880157,18,"English","# Introduction\n## Advances and challenges in gastric cancer research\n## Heterogeneity: molecular subtyping and immune microenvironment\n## Heterogeneity: cell origin and genetic mutations","[{\"question\":\"Why are current gastric cancer treatments often limited in advanced disease?\",\"answer\":\"Surgery and radio-chemotherapy face frequent challenges in advanced or metastatic stages, partly due to the lack of early diagnosis markers. Many patients also do not respond well to immunotherapies and targeted therapies, reflecting the disease’s heterogeneity.\"},{\"question\":\"What has enabled deeper understanding of gastric cancer in recent years?\",\"answer\":\"Progress includes molecular subtyping, characterization of the immune microenvironment, and defining evolutionary paths and dynamics. Tools such as genomic approaches and single-cell RNA sequencing have helped resolve cellular and transcriptional diversity in primary and metastatic lesions.\"},{\"question\":\"How do immunocompetent mouse models contribute to studying gastric cancer?\",\"answer\":\"Immunocompetent mouse models that mimic key cellular and molecular features of human GC provide platforms to elucidate mechanisms of GC pathology and immune evasion. Combined with organoid culture and clinical studies, these models also support the development of new therapeutic strategies.\"}]","Modeling human gastric cancers in immunocompetent mice - Review | PDF",1790009217,45]